Literature DB >> 16202788

Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.

Michael J Rock1, Gary Hoffman, Ronald H Laessig, Greg J Kopish, Thomas J Litsheim, Philip M Farrell.   

Abstract

OBJECTIVE: To describe the development and follow-up confirmatory results of the routine cystic fibrosis (CF) newborn screening (NBS) program in Wisconsin.
METHODS: CF NBS has been performed on a routine clinical basis in Wisconsin since July 1994. The 2-tiered immunoreactive trypsinogen (IRT)/DNA technique was used on dried blood on filter paper spots. From July 1994 to February 2002, mutation analysis was for the DeltaF508 allele. Beginning in March 2002, multimutation analysis of 25 CF mutations was performed. Infants with a positive result on NBS were seen in certified CF centers for sweat testing by means of quantitative pilocarpine iontophoresis, and families received genetic counseling.
RESULTS: From July 1994 to February 2002, there were 120 cases of CF detected by means of NBS (509,794 infants screened), with 53 DeltaF508 homozygotes and 67 compound heterozygotes. There were 8 clinically diagnosed cases of CF (no DeltaF508 allele). The CF incidence was 1:3983 (95%CI, 1:3373-1:4774). From March 2002 to June 2003, multimutation analysis identified 21 cases of classic CF (90,142 infants screened). Sweat tests were successfully performed in infants younger than 1 month.
CONCLUSIONS: Early diagnosis of CF through NBS was successfully performed, with an estimated sensitivity rate of 99% using the IRT/25 CFTR multimutation assay.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16202788     DOI: 10.1016/j.jpeds.2005.08.004

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  19 in total

1.  Newborn screening for cystic fibrosis in Alberta: Two years of experience.

Authors:  Margaret Lilley; Susan Christian; Stacey Hume; Patrick Scott; Mark Montgomery; Lisa Semple; Peter Zuberbuhler; Joan Tabak; Fiona Bamforth; Martin J Somerville
Journal:  Paediatr Child Health       Date:  2010-11       Impact factor: 2.253

2.  A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis.

Authors:  Janelle Wells; Marjorie Rosenberg; Gary Hoffman; Michael Anstead; Philip M Farrell
Journal:  Pediatrics       Date:  2012-01-30       Impact factor: 7.124

3.  Opportunities for quality improvement in cystic fibrosis newborn screening.

Authors:  Molly K Groose; Richard Reynolds; Zhanhai Li; Philip M Farrell
Journal:  J Cyst Fibros       Date:  2010-05-14       Impact factor: 5.482

4.  Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program.

Authors:  Sarah A Jadin; Grace S Wu; Zhumin Zhang; Suzanne M Shoff; Benjamin M Tippets; Philip M Farrell; Tami Miller; Michael J Rock; Hara Levy; HuiChuan J Lai
Journal:  Am J Clin Nutr       Date:  2011-03-23       Impact factor: 7.045

5.  The need for vigilance: the case of a false-negative newborn screen for cystic fibrosis.

Authors:  Christina T Dunn; Mary M Skrypek; Amy L R Powers; Theresa A Laguna
Journal:  Pediatrics       Date:  2011-07-04       Impact factor: 7.124

6.  Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies.

Authors:  Don B Sanders; Huichuan J Lai; Michael J Rock; Philip M Farrell
Journal:  J Cyst Fibros       Date:  2011-11-21       Impact factor: 5.482

7.  Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening.

Authors:  Michael J Rock; Hara Levy; Christina Zaleski; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2011-08-24

8.  Psychosocial consequences of false-positive newborn screens for cystic fibrosis.

Authors:  Audrey Tluczek; Kate Murphy Orland; Laura Cavanagh
Journal:  Qual Health Res       Date:  2010-09-17

9.  Effects of immediate telephone follow-up with providers on sweat chloride test timing after cystic fibrosis newborn screening identifies a single mutation.

Authors:  Alison La Pean; Michael H Farrell; Kerry L Eskra; Philip M Farrell
Journal:  J Pediatr       Date:  2012-10-24       Impact factor: 4.406

10.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Authors:  Philip M Farrell; Beryl J Rosenstein; Terry B White; Frank J Accurso; Carlo Castellani; Garry R Cutting; Peter R Durie; Vicky A Legrys; John Massie; Richard B Parad; Michael J Rock; Preston W Campbell
Journal:  J Pediatr       Date:  2008-08       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.